CLAVOMAF
CLAVOMAF
Amoxicillin + Clavulanic Acid
COMPOSITION:
Each film coated tablet CLAVOMAF® 1000 contains:
Amoxicillin 875 mg (as Amoxicillin Trihydrate) Clavulanic acid 125 mg (as Potassium Clavulanate)
Each film coated tablet CLAVOMAF® 625 contains:
Amoxicillin 500 mg (as Amoxicillin Trihydrate) Clavulanic acid 125 mg (as Potassium Clavulanate)
Each film coated tablet CLAVOMAF® 375 contains:
Amoxicillin 250 mg (as Amoxicillin Trihydrate) Clavulanic acid 125 mg (as Potassium Clavulanate)
Each 5 ml of CLAVOMAF® 457 for oral suspension contains:
Amoxicillin 400 mg (as Amoxicillin Trihydrate) Clavulanic acid 57 mg (as Potassium Clavulanate)
Each 5 ml of CLAVOMAF® 312 for oral suspension contains:
Amoxicillin 250 mg (as Amoxicillin Trihydrate) Clavulanic acid 62.5 mg (as Potassium Clavulanate)
Each 5 ml of CLAVOMAF® 228 for oral suspension contains:
Amoxicillin 200 mg (as Amoxicillin Trihydrate) Clavulanic acid 28.5 mg (as Potassium Clavulanate)
Each 5 ml of CLAVOMAF® 156 for oral suspension contains:
Amoxicillin 125 mg (as Amoxicillin Trihydrate) Clavulanic acid 31.25 mg (as Potassium Clavulanate)
Each one ml of CLAVOMAF® 62.5 Infant drops contains:
Amoxicillin 50 mg (as Amoxicillin Trihydrate) Clavulanic acid 12.5 mg (as Potassium Clavulanate)
DESCRIPTION:
CLAVOMAF® is a broad spectrum combination of Amoxicillin and the β-lactamase inhibitor, Potassium Clavulanate.
CLAVOMAF ® exhibits bactericidal activity against many Gram-positive and Gram-negative organisms: Staphylococcus aureus (β-lactamase and non-β-lactamase producing), Streptococcus species, Enterobacter species, E. coli, Haemophilus influenzae, Klebsiella species, Moraxella catarrhalis and Clostridium species.
Amoxicillin and Potassium Clavulanate are well absorbed from the gastrointestinal tract. CLAVOMAF ® can be given without regard to meals.
INDICATION:
CLAVOMAF ® is indicated in the following infections caused by susceptible organisms:
– Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media.
– Lower respiratory tract infections e.g. acute and chronic bronchitis, lobar and bronchopneumonia.
– Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
– Skin and soft tissue infections.
– Other infections: bone and joint infections, dental infections and intra-abdominal sepsis.
DOSAGE:
Adult and children over 12 years:
– In mild to moderate infection: one CLAVOMAF ® 625 mg tablet twice daily or one
CLAVOMAF ® 375 mg tablet three times daily.
– In severe infection and lower respiratory tract infection: one CLAVOMAF ® 1000 mg tablet twice daily or one CLAVOMAF ® 625 mg tablet three times daily.
– In dental infection: one CLAVOMAF ® 625 mg tablet twice daily or one CLAVOMAF ® 375 mg tablet three times daily for 5 days.
Children:
Children under 2 years should be dosed according to body weight.
Patients aged 12 weeks (3months) and older: as shown in the below:
– In mild to moderate infections: upper respiratory tract infections (recurrent tonsillitis), lower
respiratory tract infection, skin and soft tissue infections.
– In severe infection of upper respiratory tract infection (otitis media and sinusitis), lower
respiratory tract infections (bronchopneumonia) and urinary tract infection.
– Treatment should not be extended beyond 14 days without review to the physician.
– Pediatric patients weighing 40 kg and more should be dosed according to the adult.
– Dosage in renal impairment should be reduced.
Infants:
Based on the Amoxicillin component, CLAVOMAF ® should be used in neonates and infants aged less than 12 weeks (3 months): 30 mg/kg/day divided into 2 doses or 20 mg/kg/day
divided into 3 doses. In more serious infections the dosage may be increased up to 50 mg/kg/day divided into 3 doses.
CLAVOMAF ® Infant Drops should be administered using the supplied syringe doser.
The syringe doser has marking which correspond to the weight of the child. For example, for a child weighing 7 kg, the syringe piston should be withdrawn until the 7 kg marking is level with the top of the body of the syringe and the dose is given to child through mouth and the dose repeated each 8 hours.
For information: each 0.13 ml of CLAVOMAF ® infant Drops corresponds to 1 kg of body weight.
Over dose:
Cases of over dosage with CLAVOMAF ® are usually symptomatic. If encountered,
gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. They may be treated symptomatically, with attention to the water/ electrolyte balance. CLAVOMAF ® may be removed from the circulation by hemodialysis.
STORAGE CONDITIONS:
– Keep the medicine in a dry place at a temperature below 30 °C.
– Keep the medicine out of the reach of children.
– Protect the medicine from direct sunlight.
– Do not use Clavomaf (Tablets & Powder) after expire date